Eli Lilly and Company (LLY)vsProtalix Biotherapeutics Inc (PLX)
LLY
Eli Lilly and Company
$1,152.93
+0.04%
HEALTHCARE · Cap: $994.92B
PLX
Protalix Biotherapeutics Inc
$2.69
-0.37%
HEALTHCARE · Cap: $219.96M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 98718% more annual revenue ($79.67B vs $80.62M). LLY leads profitability with a 33.5% profit margin vs 23.5%. PLX trades at a lower P/E of 11.4x. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PLX
Buy64
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Attractively priced relative to earnings
Earnings expanding 2241.0% YoY
Every $100 of equity generates 23 in profit
Keeps 24 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 23.5%
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.3x book value
Smaller company, higher risk/reward
Weak financial health signals
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : PLX
The strongest argument for PLX centers on P/E Ratio, EPS Growth, Return on Equity. Profitability is solid with margins at 23.5% and operating margin at 23.5%. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : PLX
The primary concerns for PLX are Market Cap, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 64/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Protalix Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?